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The aim of the study is to assess the value of carbonic anhydrase isozyme IX (CA IX) expression as a predictor of disease-free survival
(DFS) and disease-specific survival (DSS) in rectal cancer treated by preoperative radio- or chemoradiotherapy or surgery only.
Archival tumour samples from 166 patients were analysed for CA IX expression by three different evaluations: positive/negative,
proportion of positivity and staining intensity. The results of immunohistochemical analysis were confirmed by demonstrating CA IX
protein in western blotting analysis. Forty-four percent of the operative samples were CA IX positive, of these 34% had weak and
66% moderate/strong staining intensity. In univariate survival analysis, intensity of CA IX expression was a predictor of DFS
(P¼0.003) and DSS (P¼0.034), both being markedly longer in tumours with negative or weakly positive staining. In multivariate Cox
model, number of metastatic lymph nodes and CA IX intensity were the only independent predictors of DFS. Carbonic anhydrase
isozyme IX intensity was the only independent predictor of DSS, with HR¼9.2 for dying of disease with moderate-intense CA IX
expression as compared with CA IX-negative/weak cases. Negative/weak CA IX staining intensity is an independent predictor of
longer DFS and DSS in rectal cancer.
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Colorectal cancer (CRC) is a common malignancy in Western
countries and the incidence is rising: there were nearly 372000 new
cases of CRC in Europe in 2002 (Ferlay et al, 2004). The most
important prognostic factors of rectal cancer are the type of surgery,
depth of invasion and nodal status. Other prognostic factors have
been widely tested (Bendardaf et al, 2006, 2007) but as yet have not
achieved an established role in the management of CRC.
Angiogenesis and tumour hypoxia have been widely studied
during the past decades to develop better treatment modalities and
prognostic factors. Angiogenesis favours tumour growth and
metastasis, whereas hypoxia renders a tumour resistant to radiation
and often to chemotherapy as well (Brizel et al,1 9 9 6 ) .H y p o x i c
regions are common in various solid cancers due to their rapid
growth. Tumour cells adapt to hypoxic conditions by stabilising the
hypoxia-inducible transcription factor (HIF-1a), which leads to
upregulation of several genes involved in cell proliferation and
angiogenesis (Harris, 2002; Semenza, 2003). One of the upregulated
genes is CA9 (Opavsky et al, 1996). CA9 encodes the carbonic
anhydrase isozyme IX (CA IX) (Wykoff et al, 2000; Niemela ¨ et al,
2007). Carbonic anhydrase isozyme IX is shown to be strongly
inducible by hypoxia in tumour cells (Wykoff et al,2 0 0 0 ) .
In earlier studies, the pattern of membranous CA IX expression is
seen in malignant cells and only rarely in normal or benign cells
(Pastorek et al, 1994; Kivela ¨ et al, 2001). Colorectal tumours show an
abnormal CA IX expression, which is especially seen in areas of high
proliferation (Saarnio et al, 1998). More diffuse staining is seen in
carcinomas than in benign lesions (Saarnio et al, 1998). Carbonic
anhydrase isozyme IX is involved in maintaining the extracellular
pH (Ivanov et al, 2001) by catalysing the reversible chemical
reaction in which carbon dioxide is hydrated to carbonic acid and
further to bicarbonate (Wykoff et al,2 0 0 0 ;B r e n n a net al, 2006).
Thus, it is an important enzyme for cancer cells in hypoxic and
normoxic conditions (Wykoff et al, 2000; Robertson et al,2 0 0 4 )i n
the regulation of acid–base balance (Hilvo et al, 2007). Interestingly,
in CRC samples studied by cDNA microarray (Talvinen et al, 2006),
CA9 was found to be the most upregulated gene.
This study was designed to assess the prognostic and predictive
value of CA IX in rectal cancer treated by either short- or long
course of radiotherapy (RT) with or without chemotherapy.
Operative samples obtained from non-irradiated patients were used
as controls. Carbonic anhydrase isozyme IX expression was studied
in relation to histopathological features and clinical data pertinent
to disease-free survival (DFS) and disease-specific survival (DSS).
PATIENTS AND METHODS
Study population
This study consists of archival operative tumour samples of 166
consecutive patients with rectal cancer, treated according to the
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sstandard protocols at Turku University Hospital. Patients in
the preoperative treatment group had been operated during
2003–2008 and those in the control group between 2000 and
2008. To have a biologically and therapeutically homogenous
study population, only tumours of the middle and lower rectum
were included. Superficial tumours that had been treated by
excision only were excluded. Standard staging included magnetic
resonance imaging or computerised tomography (CT) of the
rectum, CT of the abdomen and X-ray or CT of the thoracic area.
Since 2005, the treatments have been planned by a multi-
disciplinary team. Thirty-seven patients were treated with long-
course preoperative RT, generally by giving 50.4Gy in 6 weeks,
followed by surgery in about 4–7 weeks. Five of these patients
were treated with 5-fluorouracil and 24 with capecitabine
concomitantly with RT. Seventy-five patients were treated with
short-course RT, consisting of five fractions of 5Gy within 1 week
and surgery on the following week. Post-operative adjuvant
chemotherapy was considered for patients with lymph node-
positive or high-risk lymph node-negative tumours. As a control
group (n¼54), we studied a series of patients who had not
received any treatment before surgery. After completion of the
treatment protocols, all patients were followed up at the
Department of Surgery.
The key demographic and clinical characteristics of the
patients in the three series are summarised in Table 1. Fifty-six
percent of the patients were operated by anterior resection. The
operation was macroscopically radical in 165 (99%) patients,
microscopically radical in 154 (93%) of patients. Seventy-eight
biopsy samples from the patients who received preoperative
therapy were available for comparison with the respective
operative samples.
The study protocol was approved by the joint Ethics Committee
of Turku University and Turku University Hospital (permission
no. Dnro 4/2007, 16.1.2007) and the National Authority for
Medico-legal Affairs (permission no. 4423/32/300/02, 15.10.2002).
Evaluation of the tumour response to RT
Tumour regression grade was analysed after long-course RT in the
HE-stained sections according to the modified Dworak and Ro ¨del
scales, using three categories: poor, moderate and excellent
response (Dworak et al, 1997; Ro ¨del et al, 2005). The response
was assessed as poor, if only minimal or no tumour regression was
seen and there was a dominant tumour mass left (Dworak 0–1).
When only a few tumour cells or tumour cell groups were left in
the primary tumour, lymph nodes or perirectal fat, the response
was assessed as moderate (Dworak 2). The response was defined as
excellent, if there were only very few or no tumour cells left
(Dworak 3–4). In case of moderate and excellent response, a total
of 2–8 separate histological slides were studied to confirm the
regression grade.
Detection of CA IX expression
Carbonic anhydrase isozyme IX expression was analysed in all
preoperative diagnostic biopsies (control group excluded) avail-
able for the study, as well as in all tumour samples obtained at
operation. In each case, the most representative blocks were
selected, cut to 5mm sections and subjected to immunohisto-
chemical (IHC) staining with rabbit polyclonal antibody for CA IX
(ab15086, Abcam, Cambridge, UK). The slides were pre-treated in
microwave oven twice for 7min in 10mM sodium citrate buffer, pH
6. The antibody was diluted to a 1:8000 concentration in DAKO
Antibody diluent-solution. The staining was carried out using the
PowerVisionþ Poly-HRP IHC-kit (Immunovision Technologies,
Vision BioSystems, Norwell, MA, USA). The HE staining was
performed according to the standard laboratory protocol.
Analysis of CA IX expression
The IHC stainings of the samples were evaluated by two observers
(EK and JS), blinded to clinical and radiological information. Light
microscopes with  4 and  10 objectives (EK) and  5 and  10
objectives (JS) were used for evaluation. Carbonic anhydrase
isozyme IX staining was graded using three approaches: (1)
general grouping of the cases into positive or negative, (2)
proportion of positive staining and (3) staining intensity. The
slides were assessed as negative, if the proportion of positive
carcinoma cells in the section was less than 10%. For positive
cases, the proportion of positively stained carcinoma cells was
analysed using four categories: (i) 10–25%, (ii) 26–50% and (iii)
over 50%. The positive slides were further evaluated to determine
the staining intensity. In grading the staining intensity, three
categories were used: 0 for negative, 1 for weak and 2–3 for
moderate to strong staining intensity. Renal cell carcinoma was
used as a positive control for strong staining intensity and normal
rectal mucosa as a negative control. In weak staining intensity,
there was a faint positive staining in the cytoplasm and occasional
staining in the cell membranes impossible to detect at a small
magnification (objectives  4t o 5). The staining was assessed as
moderate or strong, if the positive reaction in the cell membranes
could easily be identified at a small magnification (objectives  4
to  5). If there were areas of a variety of staining intensities, the
predominant intensity was chosen. In preoperative biopsies, only
positive/negative staining and staining intensity were assessed, but
not the proportion of staining, because of the small size of the
samples.
Western blotting of CA IX protein
To support the IHC reaction of CA IX in this study, a small
tissue material from CRC patients (n¼4) was further studied for
CA IX protein. RNA from these tumours and corresponding
normal colorectal mucosa had been previously isolated for cDNA
microarray analysis, and CA9 was shown to be the most
upregulated gene (Talvinen et al, 2006). The protein from these
samples was isolated to confirm CA IX expression in western
blotting analysis. Total protein was quantified for each sample in
duplicate by Bio-Rad Protein Assay Dye (Bio-Rad Laboratories,
Hercules, CA, USA) and the quality was verified with Coomassie
blue staining. For western blotting, equal amounts of denaturated
protein samples were size fractioned using 10% SDS–PAGE and
electroblotted onto nitrocellulose membrane (Whatman Protran,
Perkin Elmer, Boston, MA, USA). Uniform loading and blotting
was checked with Ponceau S staining. Carbonic anhydrase isozyme
IX primary antibody (ab15086, Abcam) was diluted 1:1000 for
western detection. Horseradish peroxidase conjugated anti-rabbit
immunoglobulins (Dako, Glostrup, Denmark) and Pierce ECL
Western Blotting Substrate (Thermo Scientific, Rockford, IL, USA)
were used according to the manufacturers’ instructions for
visualisation of the signal.
Statistical analysis
All statistical analyses were run using SPSS (SPSS Inc.,
Chicago, IL, USA) and STATA (Stata Corp., College Station,
TX, USA) software packages (SPSS for Windows, version 16.0.2
and STATA/SE 10.1). Frequency tables were analysed using
the w
2-test, with the likelihood ratio (LR) or Fisher’s exact
test for categorical variables. Differences in the means of
continuous variables were analysed using Mann–Whitney’s test
or Kruskal–Wallis’s test for two and multiple independent
samples, respectively.
Inter-observer reproducibility of the CA IX assessments
was tested using regular (Cohen’s) k and weighted k.T o
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scalculate the latter, the ICC (intra-class correlation coefficient) test
was used, with parallel mode and two-way random model, using
consistency assumption and average measures option to
interpret the ICC (95% CI). Concordance of CA IX expres-
sion between preoperative biopsies and operative samples
was analysed using non-parametric paired-samples test
(Wilcoxon signed ranks test or McNemar test). The inter-observer
reproducibility of all CA IX assessments was almost perfect, with
regular k having values k¼0.988, k¼0.931 and k¼0.892, for CA
IXþ/ , staining proportion and intensity, respectively. Using
weighted k (ICC), even higher values were obtained: ICC¼0.994,
0.985 and 0.984, respectively. This indicates that all three
classifications of CA IX staining used in this study are highly
reproducible.
Univariate survival analysis for DFS and DSS was based on
the Kaplan–Meier method, where stratum-specific outcomes
were compared using log-rank (Mantel-Cox) statistics. To adjust
for covariates, Cox proportional hazards regression model was
used, covariates being entered in stepwise backward manner.
All statistical tests were two-sided and declared significant at P-value
o0.05 level.
RESULTS
General aspects of CA IX staining
Carbonic anhydrase isozyme IX staining was positive in 49% of the
diagnostic biopsies and 44% of the operative specimens. Staining
intensity was weak in 15% and moderate or strong in 29% of the
operative samples. The proportion of CA IX positive staining and
staining intensity were directly related (Spearman R¼0.917,
P¼0.0001). A low proportion of CA IX-positive staining
(10–25%) was associated with weak staining intensity and vice
versa. Negative, weak, moderate and strong staining intensity of
CA IX has been illustrated in Figure 1. The results of IHC analysis
were confirmed by the demonstration of CA IX protein in western
blotting analysis (Figure 2).
The expression of CA IX in the diagnostic biopsies and
respective operative specimens
Biopsy samples (B) stained for CA IX were compared with the
respective operative samples (S). Using CA IX positive/negative
(þ/ ) grading, 48 out of 78 (61%) B–S pairs were concordant and
30 out of 78 (39%) were discordant. Of the discordant samples,
positive CA IX expression in biopsies was downregulated in 18 out
of 38 (48%) cases, and negative CA IX expression was upregulated
in 12 out of 40 (30%) cases. Using CA IX intensity evaluation 43
out of 78 (55%) B–S pairs were concordant and 35 out of 78 (45%)
were discordant. In pairwise comparison (Wilcoxon), CA IX
expression pattern in B–S pairs was not significantly different,
P¼0.268 and 1.000 for CA IXþ/  and CA IX intensity,
respectively. Results of staining intensity in the biopsy specimens
are shown in Table 2.
CA IX staining intensity compared with traditional
prognostic factors
In Table 3, the intensity of CA IX staining is compared with the
traditional prognostic factors and survival. When the long-course
RT group was divided into two treatment categories (with or
without concomitant chemotherapy), there was a statistically
significant difference in staining intensity (P¼0.006) between
the groups, showing more intense staining in the group that had
not received concomitant chemotherapy. Tumour regression grade
was possible to be evaluated in 36 long-course RT group patients.
The staining was more intense in the poor response group than in
the moderate/excellent response group (P¼0.010). On the other
hand, CA IX expression pattern was not significantly associated
with the size, nodal status or grade of the tumour, number of
examined lymph nodes, resection type or its radicality, circum-
ferential-, proximal- or distal margins, vessel invasion, tumour
necrosis or patient gender.
Prognostic factors predicting survival
In univariate survival (Kaplan–Meier) analysis, patients with
negative or weak CA IX staining intensity had significantly longer
DFS (P¼0.001), as depicted in Figure 3A. Also, DSS was
significantly (P¼0.009) longer among patients who had tumours
with negative or weak CA IX staining intensity (Figure 3B). To
analyse CA IX staining intensity as independent predictor of DFS
and DSS, the following variables were entered in the multivariate
(Cox) proportional hazards regression model: sex, age (young/old
with median age as cutoff), treatment series (short-course RT,
long-course RT and control group), preoperative tumour assess-
ment (T), blood vessel invasion (yes/no), number of metastatic
lymph nodes (LNN) (with four positive LNN as cutoff) and CA IX
staining intensity. In this multivariate model, only two variables
were independent predictors of DFS: (1) number of metastatic
Table 1 The clinical characteristics of the patients
Short-
course
RT, n (%)
Long-
course
RT, n (%)
Control,
n (%)
Total,
n (%) P-value
Study population
Female 26 (38) 13 (19) 29 (43) 68 0.069
Male 49 (50) 24 (24) 25 (25) 98
Age (mean) 65.6 65.7 72.1 67.6 0.002
Preoperative T
a
T1–2 24 (75) 0 (0) 8 (25) 32
0.0001 T3 44 (81) 2 (4) 8 (15) 54
T4 1 (3) 34 (92) 2 (5) 37
TX 6 (14) 1 (2) 36 (84) 43
Postoperative T
a
T1 3 (30) 2 (20) 5 (50) 10
T2 29 (64) 4 (8) 15 (31) 48
T3 40 (43) 20 (22) 32 (35) 92 0.001
T4 2 (14) 10 (71) 2 (14) 14
No vital cancer cells left 1 (50) 1 (50) 0 (0) 2
Postoperative tumour differentiation grade (G)
b
G1 6 (24) 7 (28) 12 (48) 25
0.043 G2 50 (47) 24 (22) 33 (31) 107
G3 17 (59) 3 (10) 9 (31) 29
GX 2 (40) 3 (60) 0 (0) 5
Circumferential margin (crm)
c
0mm 2 (18) 7 (64) 2 (18) 11
0.005 p1mm 3 (33) 4 (44) 2 (22) 9
1.1mmp crm p2mm 1 (20) 2 (40) 2 (40) 5
42mm 55 (62) 17 (19) 16 (18) 88
Disease-specific outcome
Alive without
recurrence
59 (54) 20 (18) 31 (28) 110
0.015 Alive with recurrence 5 (31) 7 (44) 4 (25) 16
Died of disease 7 (25) 9 (8) 12 (43) 28
Died of other causes 4 (33) 1 (8) 7 (58) 12
RT¼radiotherapy.
aT1¼tumour invades submucosa, T2¼tumour invades the
muscular layer, T3¼tumour invades through the muscular layer, T3¼tumour
invasion through the muscular layer, T4¼tumour invasion of other organs or
structures and/or perforation of the visceral peritoneum, TX¼unknown.
bG1¼well-
differentiated, G2¼moderately and G3¼poorly differentiated tumour,
GX¼unknown.
ccrm¼not measured from all tumours.
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sLNN; HR¼4.44 (95% CI 1.37–14.38) (P¼0.013) for disease
recurrence if X4 metastatic nodes and (2) CA IX intensity;
HR¼7.54 (95% CI 2.44–23.28) (P¼0.003) for recurrence, if
moderate-intense CA IX expression (CA IX-negative/weakly
positive cases as reference) was present. In a similar Cox model,
only CA IX intensity remained as significant independent
predictor of DSS, with HR¼9.23 (95% CI 2.26–37.64) for dying
of disease with moderate-intense CA IX expression, as compared
with CA IX-negative/weakly positive cases as reference. From the
survival curves, the cumulative proportion of survivors at the
36-month follow-up time point was 83 and 35% for CA IX
negative/weak and moderate/strong groups, respectively.
DISCUSSION
In this study, CA IX expression pattern was analysed from
the samples of 166 patients, of whom 29 had received pre-
operative chemoradiotherapy, 8 patients long-course RT without
chemotherapy, 75 short-course RT and 54 patients had no therapy
before surgery. The intensity of CA IX expression was shown to be
a significant prognostic factor in this study. When analysed with
univariate (Kaplan–Meier) survival model, we found that the
intensity of CA IX expression was significantly related to both DFS
and DSS. Patients whose tumours were negative or weakly positive
in CA IX staining had better prognosis. The difference in DFS
between patients with negative/weak staining intensity and those
with moderate/strong staining intensity was evident from the early
postoperative period, and the difference increased over time to
about 50% at 3 years. This is important while considering potential
interventions with adjuvant therapies. Similar data have not been
previously reported in rectal cancer.
When examined in multivariate (Cox) proportional hazards
regression model controlled for several covariates, CA IX intensity
together with the number of metastatic lymph nodes were shown
to be independent predictors of DFS. Carbonic anhydrase isozyme
Figure 1 Immunohistochemistry of CA IX in rectal cancer. (A) Negative, (B) weak, (C) moderate and (D) strong staining intensity. The proportion of
carcinoma cells with membranous reaction increases along with the general staining intensity (scale bar¼20mm).
56 kDa
T1 T2 T3 T4 N1 N2 N3 N4
50 kDa
Figure 2 Western blotting analysis of CA IX in colorectal cancer (T) and
normal colorectal mucosa (N). Strong bands with the molecular weights of
50 and 56kDa can be seen in tumours T1–2 and T4, which were also
positive for CA IX in the immunohistochemical slides. Instead, samples
from the normal colorectal mucosa (N1–4) and one tumour (T3) had only
a faint band of 50kDa, all of which were also negative for CA IX in the
corresponding immunohistochemical slides.
Table 2 CA IX expression in the three patient series
Short course
RT, n (%)
Long
course
RT
a, n (%)
Control,
n (%)
Total,
n (%) P-value
Preoperative biopsies
Staining intensity
Negative 27 (49) 14 (56)
b 41 (51)
Weak 18 (33) 5 (20)
b 23 (28) 0.478
Moderate/
strong
10 (18) 6 (24)
b 16 (20)
Operative samples
Positive proportion
o10%
(negative)
45 (60) 21 (57) 26 (48) 92 (55) 0.387
10–25% 18 (24) 7 (19) 12 (22) 37 (22)
26–50% 8 (11) 5 (14) 6 (11) 19 (11)
450% 4 (5 ) 4 (11) 10 (19) 18 (11)
CA IX¼carbonic anhydrase isozyme IX; NA¼Not available; RT¼radiotherapy.
aIncluding patients treated with long-course RT with or without chemotherapy.
bNot
available.
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These data implicate that intensity of CA IX expression seems to be
a powerful independent prognostic factor, not confounded by the
mode of treatment or other established prognostic factors
(Giatromanolaki et al, 2001).
This study could not show a correlation between the expression
of CA IX and other clinical or histopathological factors. Most
of the patients in this study had received RT with or without
chemotherapy before operation, which may have an influence on
tumour size, stage and grade, nodal status and consequently, CA
IX staining in the operative sample. To compensate this problem,
CA IX expression was compared with the preoperative biopsies
and respective surgical specimens. However, some of the available
diagnostic biopsy samples were scarce, precluding adequate
comparison of all sample pairs.
Carbonic anhydrase isozyme IX staining intensity in the
operative samples was shown to be significantly different among
the treatment categories. The same was also true among patients
with different response to therapy, which was analysed from the
long-course RT group specimens. Most tumours in this group that
had been treated with long-course RT without chemotherapy were
CA IX positive with moderate/strong staining intensity. Instead,
tumours that had been treated with chemoradiotherapy were
mostly CA IX negative. This may imply that chemotherapy can act
Table 3 CA IX expression in the operative samples related to key
clinical variables
Staining intensity, n (%)
Variable Negative Weak
Moderate/
strong P-value
Preoperative therapy
Short-course RT 45 (60) 12 (16) 18 (24)
0.006 Long-course RT only 1 (12) 0 (0) 7 (87)
Long-course RT+
chemotherapy
20 (69) 1 (3) 8 (28)
Control 26 (48) 12 (22) 16 (30)
Postoperative T
a
pT1 7 (70) 2 (20) 1 (10)
pT2 31 (65) 5 (10) 12 (25)
pT3 47 (51) 16 (17) 29 (31) 0.285
pT4 6 (43) 1 (7) 7 (50)
No vital cancer 1 (50) 1 (50) 0 (0)
Postoperative nodal status (N)
b
N1 28 (62) 6 (13) 11 (24)
0.277 N2 11 (44) 5 (20) 9 (36)
N0 52 (55) 12 (13) 29 (31)
NX 1 (33) 1 (33) 1 (33)
Postoperative tumour differentiation grade (G)
c
G1 18 (72) 5 (20) 2 (8)
0.168 G2 55 (51) 16 (15) 36 (34)
G3 16 (55) 3 (10) 10 (34)
GX 3 (60) 1 (20) 1 (20)
Post-RT tumour regression
d
Poor 7 (37) 1 (5) 11 (58)
0.010 Moderate/excellent 14 (82) 0 (0) 3 (18)
CA IX¼carbonic anhydrase isozyme IX; RT¼radiotherapy.
aT1¼tumour invades
submucosa, T2¼tumour invades the muscular layer, T3¼tumour invades through
the muscular layer, T4¼tumour invasion of other organs or structures and/or
perforation of the visceral peritoneum, TX¼unknown.
bN1¼1–3,N2¼more than
four metastatic lymph nodes, N0¼no metastatic lymph nodes, NX¼unknown.
cG1¼well-differentiated, G2¼moderately and G3¼poorly differentiated tumour,
GX¼unknown.
dEvaluated from 36 long-course RT group patients.
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Figure 3 (A) Intensity of CA IX expression as determinant of disease-
free survival in univariate (Kaplan–Meier) survival analysis. (B) Intensity of
CA IX expression as determinant of disease-specific survival in univariate
(Kaplan–Meier) survival analysis.
Table 4 Carbonic anhydrase IX (CA IX) as a prognostic marker in
various types of cancer
Type of cancer
Prognostic/
predictive
significance of high
CA IX Expression Reference
Non-small-cell lung
cancer
Unfavourable Giatromanolaki et al, 2001; Swinson
et al, 2003; Kim et al, 2005; Kon-no
et al, 2006; Simi et al, 2006
Bladder cancer Hoskin et al, 2003
Breast cancer Unfavourable Chia et al, 2001; Brennan et al,
2006; Generali et al, 2006; Hussain
et al, 2007; Trastour et al, 2007
Oligodendroglial
brain tumour
Unfavourable Ja ¨rvela ¨ et al, 2008
Head and neck
cancer
Unfavourable Bache et al, 2006; Kappler et al,
2008
Renal clear cell
carcinoma
Favourable Bui et al, 2003, 2004; Atkins et al,
2005; Patard et al, 2008
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sas a radiosensitiser and improve tumour oxygenation and
consequently also final treatment outcome. This finding can
presumably have important therapeutic implications in other
tumour types as well.
Tumour oxygenation is known to have an effect on patient
prognosis. In advanced cancer of the uterine cervix, Hockel et al
(1996) showed that low oxygen pressure was associated with larger
tumours and more frequent parametrial spread as compared with
tumours of the same stage and higher oxygen pressure. Patients
with hypoxic tumours had poorer disease outcome (Hockel et al,
1996). Hypoxia induces CA IX, especially in or near necrotic
regions (Wykoff et al, 2000) and in areas with high proliferation
(Saarnio et al, 1998). Preoperative treatment can shrink the
tumour and even complete remissions are seen (Ruo et al, 2002).
As the tumour shrinks, its oxygenation may improve. Hence,
preoperative therapy may reduce tumour hypoxia and thereby CA
IX expression may be downregulated. In this study, there were two
histologically complete responses after preoperative therapy. One
complete response was unexpectedly seen after short-course RT
(Marijnen et al, 2001), which remains to be explained but may
have been related to exceptional radiosensitivity.
The present data are in alignment with the results reported in
other human malignancies, where CA IX expression has been
shown to be a prognostic marker as well (Table 4). This includes
non-small-cell lung cancer (studied by Swinson et al (2003) and
Giatromanolaki et al (2001)), bladder cancer (Hoskin et al, 2003),
invasive breast cancer (Chia et al, 2001; Brennan et al, 2006) and
oligodendroglioma (Ja ¨rvela ¨ et al, 2008). Interestingly, in renal
cancer, low CA IX expression and absence of VHL mutation were
related to a more advanced tumour and unfavourable outcome
(Patard et al, 2008). Currently, antibodies against CA IX are being
studied in phase three trials in the treatment of renal cancer
(Pastorekova et al, 2007). Also, sulphonamides have been tested
for therapeutic purposes against CA IX for several years
(Pastorekova et al, 2007). It is possible that this strategy will also
be evaluated in the treatment of other types of tumours.
To our knowledge, this is the first study to report the important
prognostic significance of CA IX in rectal cancer. This study shows
that strong staining intensity of CA IX is an adverse prognostic
factor in rectal cancer. Further studies are needed to evaluate its
potential therapeutic implications.
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